Last updated: September 9, 2026
Diphenhydramine hydrochloride and pseudoephedrine hydrochloride are mature, low-cost OTC active ingredients used together in allergy and cold products. Their commercial value is driven by brand recognition, retail distribution, seasonal demand, pharmacy access, and formulation execution rather than composition-of-matter patents. The combination has limited regulatory exclusivity, minimal Paragraph IV exposure, and low manufacturing barriers. Revenue growth is likely to remain modest, with private-label products capturing volume and branded products retaining a premium through convenience, trust, and shelf visibility.
What products contain diphenhydramine hydrochloride and pseudoephedrine hydrochloride?
The combination is used in oral products that treat nasal congestion, runny nose, sneezing, and allergy symptoms. A common U.S. formulation contains diphenhydramine hydrochloride 25 mg and pseudoephedrine hydrochloride 30 mg per tablet.
| Product characteristic |
Typical U.S. position |
| Antihistamine |
Diphenhydramine hydrochloride |
| Nasal decongestant |
Pseudoephedrine hydrochloride |
| Common adult strength |
Diphenhydramine 25 mg plus pseudoephedrine 30 mg |
| Dosage forms |
Tablets, caplets, liquid products, and store-brand equivalents |
| Primary channels |
Pharmacies, mass retailers, grocery stores, e-commerce, and behind-the-counter pharmacy sales |
| Regulatory category |
OTC monograph or legacy OTC product pathways, depending on the product |
| Main branded competitors |
Benadryl Allergy Plus Congestion, Sudafed combination products, and private-label equivalents |
Kenvue markets the Benadryl brand in the United States. Product ownership and distribution arrangements can differ by country. The active ingredients are also sold by numerous generic manufacturers and retailers under store brands.
Diphenhydramine is a first-generation antihistamine with sedating and anticholinergic effects. Pseudoephedrine is a systemic sympathomimetic decongestant. The pharmacologic combination addresses symptoms that often occur together but also creates safety and labeling constraints, particularly drowsiness from diphenhydramine and cardiovascular effects from pseudoephedrine.
What is the FDA regulatory status of the combination?
FDA regulation of these products is based primarily on OTC monograph conditions and product-specific compliance rather than newly granted market exclusivity.
Diphenhydramine is recognized as an OTC antihistamine active ingredient for applicable cold, allergy, and related indications under 21 C.F.R. Part 341. Pseudoephedrine is recognized as an OTC oral nasal decongestant active ingredient under the same regulatory framework (Electronic Code of Federal Regulations, n.d.-a).
A compliant OTC product must satisfy requirements covering:
- Active ingredient concentration
- Permitted indications
- Warnings and contraindications
- Directions for use
- Age restrictions
- Package labeling
- Manufacturing and quality standards
The FDA has proposed removing oral phenylephrine from the OTC monograph for nasal congestion after concluding that the available data do not support its effectiveness at the monograph dose. That proposal concerns phenylephrine, not pseudoephedrine. The distinction may benefit pseudoephedrine-based products if consumers and retailers shift away from oral phenylephrine decongestants (FDA, 2024).
Pseudoephedrine remains subject to retail controls under the Combat Methamphetamine Epidemic Act. Products are generally sold behind the pharmacy counter, with purchase limits, identification requirements, sales logs, and retailer compliance obligations. These restrictions raise transaction costs and reduce impulse purchasing but do not eliminate demand (U.S. Drug Enforcement Administration, n.d.).
When does diphenhydramine and pseudoephedrine lose exclusivity?
The active ingredients have no meaningful remaining composition-of-matter exclusivity. Diphenhydramine and pseudoephedrine have been marketed for decades, and multiple manufacturers supply the ingredients and finished products.
| Exclusivity category |
Current position |
| Diphenhydramine composition patent |
Expired |
| Pseudoephedrine composition patent |
Expired |
| Combination composition patent |
No known commercially material blocking patent |
| FDA new chemical entity exclusivity |
None |
| OTC monograph exclusivity |
No conventional Hatch-Waxman exclusivity |
| Brand trademark protection |
Continues while marks are maintained and used |
| Product-specific formulation protection |
Potentially available but generally narrow and commercially limited |
| Regulatory exclusivity |
Not a material current value driver |
There is no single patent expiration date that controls market entry for the combination. Generic or private-label competition can enter through compliant OTC pathways without waiting for the expiration of an originator patent covering the active ingredients.
What patents protect diphenhydramine hydrochloride and pseudoephedrine hydrochloride products?
The commercial patent estate is weak at the active-ingredient level. Potential protection is more likely to involve a specific formulation, delivery system, packaging configuration, or manufacturing process.
Formulation patents
Possible formulation claims could cover:
- Extended-release or timed-release delivery
- Bilayer tablets separating the antihistamine and decongestant
- Liquid stability systems
- Taste-masking technology
- Specific excipient combinations
- Reduced-drowsiness or modified-release profiles
- Unit-dose packaging
- Combination products containing additional active ingredients
These rights would not necessarily block conventional immediate-release tablets containing diphenhydramine and pseudoephedrine. Their value depends on whether the formulation has meaningful consumer acceptance, regulatory differentiation, or distribution scale.
Method-of-use patents
Method-of-use patent value is limited because the principal indications, including temporary relief of nasal congestion, runny nose, sneezing, and allergy symptoms, are longstanding and reflected in OTC labeling. A later patent could target a narrower population, dosing schedule, or therapeutic application, but such claims would face substantial validity and obviousness risks.
Manufacturing and process patents
Manufacturing patents may cover crystallization, impurity control, particle-size distribution, or high-throughput tableting. These rights can reduce process costs or improve quality but usually do not prevent competitors from producing the same active ingredients through alternative methods.
What is the Orange Book status of these products?
Conventional OTC monograph-compliant products containing diphenhydramine and pseudoephedrine generally do not have an Orange Book listing that functions like an NDA-based patent barrier.
The FDA Orange Book is principally used for approved prescription drug products and approved products with associated patent and exclusivity information. OTC products can have NDA histories in specific circumstances, but the ordinary generic and store-brand market for these ingredients is not controlled by a listed patent estate equivalent to that of a modern prescription product (FDA, n.d.-a).
This regulatory posture affects litigation strategy. A competitor generally does not need to file an ANDA with a Paragraph IV certification to launch a standard monograph-compliant OTC product. The market is therefore more exposed to direct formulation competition, private-label substitution, and retailer sourcing decisions.
Are there Paragraph IV challenges or patent litigation risks?
There is no major Paragraph IV dispute that defines the current U.S. market for the standard diphenhydramine-pseudoephedrine combination.
The principal reasons are:
- The active ingredients are long off-patent.
- Standard products can rely on OTC monograph conditions.
- No widely recognized blocking Orange Book patents control the conventional combination.
- Commercial disputes are more likely to involve trademarks, packaging, advertising, supply agreements, or product-specific formulations.
Patent litigation risk can still arise if a company launches an extended-release product or a technically differentiated delivery system covered by a live patent. That risk would be product-specific rather than inherent to diphenhydramine or pseudoephedrine.
Trademark disputes are more commercially relevant. Brand owners can challenge confusingly similar names, packaging, trade dress, and consumer claims. Those disputes generally protect marketing assets rather than the active-ingredient combination.
How strong is the patent estate for the combination?
The patent estate is weak for conventional immediate-release products and moderate at most for differentiated delivery systems.
| Patent factor |
Assessment |
| Composition-of-matter protection |
Very weak or absent |
| Standard tablet protection |
Weak |
| OTC regulatory barrier |
Low |
| Extended-release formulation protection |
Potentially moderate |
| Brand and trade-dress protection |
Stronger than patent protection |
| Manufacturing barrier |
Low to moderate |
| Retail access barrier for pseudoephedrine |
Moderate |
| Biosimilar barrier |
Not applicable |
The most defensible commercial assets are brand equity, retailer relationships, compliant supply, packaging, and consumer recognition. A company relying only on the active ingredients has limited ability to sustain premium pricing.
How does the combination compare with phenylephrine products?
Pseudoephedrine-based products have a stronger decongestant position than oral phenylephrine products because the FDA has proposed determining that oral phenylephrine is not effective at the monograph dose. The proposal does not automatically remove all phenylephrine products from the market, but it creates regulatory and commercial pressure on manufacturers and retailers (FDA, 2024).
| Factor |
Pseudoephedrine combination |
Oral phenylephrine combination |
| FDA effectiveness position |
Remains recognized for applicable OTC use |
FDA proposed removal from monograph |
| Pharmacy access |
Behind-the-counter restrictions |
Generally front-of-store |
| Consumer convenience |
Lower |
Higher |
| Decongestant efficacy position |
More favorable |
Under regulatory challenge |
| Retail complexity |
Higher |
Lower |
| Competitive outlook |
Stable with possible share gains |
Greater reformulation and delisting risk |
If retailers reduce oral phenylephrine assortments, pseudoephedrine products may gain demand. The gain will be limited by behind-the-counter controls, inventory policies, and consumer movement toward nasal sprays or non-drug remedies.
What companies are challenging the market?
The market is fragmented rather than dominated by a small group of patent challengers. Competition comes from:
- Kenvue and the Benadryl brand
- Other national OTC brand owners
- Store-brand and pharmacy-brand manufacturers
- Contract manufacturers supplying private-label retailers
- Nasal decongestant products containing oxymetazoline
- Intranasal corticosteroids for allergic rhinitis
- Non-sedating antihistamines such as cetirizine, loratadine, and fexofenadine
- Single-ingredient pseudoephedrine products
- Combination products using other antihistamines or decongestants
The most important competitive substitution is therapeutic rather than patent-driven. Consumers may choose a non-sedating antihistamine for allergy symptoms, an intranasal product for congestion, or a single-ingredient product to avoid unnecessary exposure to two active ingredients.
What is the financial trajectory for diphenhydramine and pseudoephedrine products?
The financial trajectory is mature, defensive, and volume-sensitive. The category can produce reliable cash flow but has limited structural growth.
Revenue drivers
Revenue is supported by:
- Seasonal allergy and cold incidence
- Established consumer awareness
- Low-cost manufacturing
- Broad retail distribution
- Demand for nighttime or multisymptom relief
- Potential substitution away from oral phenylephrine
- Private-label expansion
Revenue is constrained by:
- Low unit prices
- Heavy generic competition
- Retailer bargaining power
- Pseudoephedrine purchase restrictions
- Diphenhydramine sedation concerns
- Substitution by newer antihistamines
- Consumer preference for single-ingredient therapy
- Limited ability to increase price without volume loss
Public companies generally report these products within broader consumer-health segments rather than as standalone brands. That prevents a reliable public estimate of revenue or margin for the specific diphenhydramine-pseudoephedrine combination. The economic profile is nevertheless clear: branded products earn higher gross margins, while private-label products compete primarily on price and retailer access.
Five-year commercial outlook
| Period |
Expected market dynamic |
| 2025-2026 |
Stable demand, with possible benefit from declining confidence in oral phenylephrine |
| 2026-2028 |
Continued private-label pressure and gradual substitution toward non-sedating or intranasal products |
| 2028-2030 |
Low unit growth; profitability determined by procurement, packaging, and channel mix |
| Longer term |
Mature OTC cash flow with limited patent-supported pricing power |
A branded product can preserve revenue through strong shelf placement, advertising, packaging refreshes, and claims focused on symptom coverage. It cannot rely on patent exclusivity to prevent lower-priced substitutes.
What licensing deals affect the market?
No major publicly disclosed licensing transaction appears to control the active-ingredient market. Commercial arrangements are more likely to involve:
- Trademark licensing
- Contract manufacturing
- Private-label supply
- Retail distribution
- Regional brand rights
- Packaging and merchandising agreements
These agreements can affect market share and gross margin, but they do not create a durable barrier around diphenhydramine or pseudoephedrine. Brand ownership and supply reliability are more important than drug patent licensing.
What generic entry risks exist?
Generic and private-label entry risk is high for conventional immediate-release products. The launch path is comparatively simple because the ingredients are established, manufacturing capability is widespread, and consumer switching costs are low.
The main barriers are operational:
- Compliance with pseudoephedrine sales controls
- Reliable API sourcing
- FDA-compliant labeling
- Retailer qualification
- Forecasting seasonal demand
- Inventory management
- Product liability controls
- Avoidance of misleading comparative claims
A new entrant with no brand support would likely compete on price, retailer placement, and supply reliability. A premium entrant would need a differentiated delivery system, lower-sedation positioning, packaging advantage, or a strong distribution partner.
Is biosimilar risk relevant?
Biosimilar risk is not relevant. Diphenhydramine hydrochloride and pseudoephedrine hydrochloride are small-molecule chemical drugs, not biologics. Competition comes from generic, authorized-generic, private-label, and branded OTC products rather than biosimilar products.
Key Takeaways
- Diphenhydramine hydrochloride and pseudoephedrine hydrochloride are mature OTC ingredients with no meaningful composition-of-matter exclusivity.
- Conventional products face high generic and private-label competition.
- The market is not controlled by a major Orange Book patent estate or active Paragraph IV campaign.
- Formulation, manufacturing, packaging, trademark, and distribution rights are more commercially relevant than active-ingredient patents.
- Pseudoephedrine remains available but is subject to behind-the-counter sales controls under federal law.
- FDA action against oral phenylephrine could support relative demand for pseudoephedrine products.
- Long-term revenue is likely to be stable to modestly declining in units, with branded products relying on price, distribution, and consumer trust.
- The strongest commercial risks are therapeutic substitution, retailer pricing pressure, and private-label penetration.
FAQs
Does diphenhydramine hydrochloride have a patent expiration date?
Its original composition-of-matter protection expired decades ago. No active ingredient patent controls ordinary OTC diphenhydramine products.
Is pseudoephedrine hydrochloride prescription-only?
No. In the United States, pseudoephedrine is generally available without a prescription but is sold behind the pharmacy counter and subject to purchase limits and recordkeeping requirements.
Can a company launch a generic diphenhydramine-pseudoephedrine tablet without a Paragraph IV filing?
A conventional OTC monograph-compliant product generally does not require an ANDA Paragraph IV filing. Product-specific NDA or formulation patents could change that analysis.
Which product has greater commercial value, diphenhydramine alone or the combination?
The combination can command a higher retail price because it treats multiple symptoms, but diphenhydramine-alone products have broader formulation flexibility and may face fewer pseudoephedrine-related purchasing restrictions.
Could oral phenylephrine regulatory action increase pseudoephedrine sales?
Yes. Retailers and consumers may shift toward pseudoephedrine products if oral phenylephrine products are removed or reduced. The effect will be limited by behind-the-counter access and competition from nasal sprays.
References
-
Electronic Code of Federal Regulations. (n.d.-a). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341
-
U.S. Food and Drug Administration. (2024). FDA proposes ending use of oral phenylephrine as OTC monograph nasal decongestant ingredient. https://www.fda.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Drug Enforcement Administration. (n.d.). Combat methamphetamine epidemic act requirements for retail sellers of scheduled listed chemical products. https://www.deadiversion.usdoj.gov/
